Mesenchymal Cell News 11.21 June 4, 2019 | |
| |
TOP STORYIntrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy Utilizing a dose-escalation design, scientists delivered between 10 and 200 million adipose-derived autologous MSCs intrathecally to patients with early multiple system atrophy (MSA). Patients were closely followed with clinical, laboratory, and imaging surveillance. Primary endpoints were frequency and type of adverse events; key secondary endpoint was the rate of disease progression assessed by the Unified MSA Rating Scale. [Neurology] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)IN VITROInvestigators proposed the development of tissue engineered biomaterials that mimic the zonal cartilage organization and extracellular matrix composition through the use of a microfluidic printing head bearing a mixing unit and incorporated into an extrusion-based bioprinter. The system was devised so that multiple bioinks could be delivered either individually or at the same time and rapidly mixed to the extrusion head, and finally deposited through a coaxial nozzle. [Biofabrication] Abstract Single-Cell Transcriptomes of Murine Bone Marrow Stromal Cells Reveal Niche-Associated Heterogeneity Using single cell RNA sequencing, the authors explored the functional and phenotypic heterogeneity of individual transcriptomes of 1,167 murine bone marrow MSCs. These cells exhibited a tremendous heterogeneity of gene expression, which precluded the identification of defined subpopulations. [Eur J Immunol] Abstract Scientists found that human adipose-derived stem cell morphology, cilia length and cilia conformation varied in response to culture in complete growth, osteogenic differentiation, or adipogenic differentiation medium, with the longest cilia expressed in adipogenically differentiating cells. [Sci Rep] Full Article Researchers explored the applicability, cellular efficacy, and osteogenic activities of porous nano-hydroxyapatite (N-HA)/poly-grafted maleic anhydride (PGS-g-M) composite scaffolds. Nuclear magnetic resonance analyses indicated that approximately 43% of the hydroxide radicals in PGS were displaced by maleic anhydride. [Sci Rep] Full Article Human bone-marrow derived MSCs were obtained via human bone marrow. During osteogenic induction and differentiation, cells were transfected with different plasmids with the intention of investigating the roles of miR‐200c on osteogenic differentiation, calcium salt deposition, alkaline-phosphatase activity, mineralized nodule formation, osteocalcin content, and proliferation of osteoblasts. [J Cell Physiol] Abstract Investigators presented a new strategy to produce different combinations of decellularized cultured cell-derived extracellular matrix obtained from different cultured cell types, namely MSCs and human umbilical vein endothelial cells (HUVECs), as well as the co-culture of MSCs:HUVECs and investigated the effects of its various compositions on cell metabolic activity, osteogenic differentiation and angiogenic properties of human bone marrow-derived MSCs, vital features for adult bone tissue regeneration and repair. [J Tissue Eng Regen Med] Abstract Scientists used liquid chromatography tandem-mass spectrometry to identify the proteins expressed by mouse adipose-derived-MSCs (mAdMSCs) isolated from normal mice and mice with severe combined immunodeficiency. The protein expression profiles of each strain were 98%–100% identical, indicating that the expression levels of major proteins potentially associated with the therapeutic effects of mAdMSCs were highly similar. [Int J Mol Sci] Full Article IN VIVOResearchers report a new strategy for loading crosslinked hyaluronic acid gel (HA gel) with MSC-secretome (Sec). The HA gel/MSC-Sec treatment paradigm created a sustained release system that repaired endometrial injury in rats and promoted viable pregnancy. [Adv Healthc Mater] Abstract Investigators explored the role of GNAS in osteogenic differentiation of MSCs. A total of 85 GNASf/f male mice were selected for animal experiments and 10 GNASf/f male mice for bone-marrow derived (B)MSCs isolation to conduct cell experiments. The mice and BMSCs were treated with Verteporfin to inhibit the Hippo signaling pathway or recombinant adenovirus-expressing Cre to knockout the GNAS expression. [J Cell Physiol] Abstract Subscribe to one of our other 19 science newsletters such as ESC & iPSC News & Cell Therapy News. | |
| |
REVIEWSAlly to Adversary: Mesenchymal Stem Cells and Their Transformation in Leukemia The authors underline the current understanding of the physiological and pathophysiological roles of MSCs and its transformation in diseased state, laying stress on developing further understanding of MSC regulation for development of the latter as therapeutic targets. [Cancer Cell Int] Full Article Emerging Therapies for Cartilage Regeneration in Currently Excluded ‘Red Knee’ Populations Investigators systematically reviewed cartilage repair clinical trials to identify common exclusion criteria and reviewed the literature to identify emerging regenerative approaches that are poised to overcome these current exclusion criteria. The term “knee carilage repair” was searched on clinicaltrials.gov. Of the 60 trials identified on initial search, 33 were further examined to extract exclusion criteria. [Regen Med] Full Article Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field. | |
| |
SCIENCE NEWSBrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting BrainStorm Cell Therapeutics Inc. on World Multiple Sclerosis (MS) Day presented a poster of the Company’s ‘Phase II Open-Label, Multicenter Study of Repeated Intrathecal Administration of Autologous MSC-NTF cells in Progressive MS’. [Press release from BrainStorm Cell Therapeutics Inc. discussing research presented at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting] Press Release | |
| |
INDUSTRY NEWSCalidi Biotherapeutics, Inc. announced their ongoing scientific collaboration with David F. Stroncek, MD, Chief, Cell Therapy Section at the Department of Transfusion Medicine, NIH to jointly study the impact of different stem cell carriers on the therapeutic potential of oncolytic viruses in the treatment of cancer. [Calidi Biotherapeutics, Inc.] Press Release BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase II Study BrainStorm Cell Therapeutics Inc. announced that the Stanford University School of Medicine will serve as the second contracted clinical study site for the company’s Phase II open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis. [BrainStorm Cell Therapeutics Inc.] Press Release | |
| |
POLICY NEWSFDA Wins Major Victory in Campaign against Stem Cell Clinic The US FDA won a major legal victory in its ongoing effort to crack down on clinics marketing bogus and potentially hazardous stem cell products. A federal judge in Miami granted the FDA an injunction to prevent the Florida-based US Stem Cell Clinic from offering treatments designed to create stem cells from body fat and administering them intravenously or directly into the spinal cords of patients to treat Parkinson’s disease, amyotrophic lateral sclerosis, chronic obstructive pulmonary disease and other serious conditions. [CNN] Editorial Controversial US Bill Would Lift Supreme Court Ban on Patenting Human Genes A congressional proposal that would overturn a landmark US Supreme Court decision that barred the patenting of human genes and ease other restrictions on patenting software and biomedical inventions is drawing fierce criticism from some scientific societies and patient advocates. [ScienceInsider] Editorial China Urged to Abandon Plan to Sell Unproven Cell Therapies An international group of stem-cell researchers is urging China to cancel draft regulations that would permit some hospitals to sell therapies developed from patients’ own cells, without approval from the nation’s drug regulator. [Nature News] Editorial Brexit ‘May Bar UK Scientists From €100bn EU Research Fund’ The Horizon Europe program will fund €100bn in research projects, making it one of the largest science funds in the world. British researchers will be locked out unless the government negotiates an access deal in the coming months. [The Guardian] Editorial
| |
EVENTSNEW 7th Annual German Stem Cell Network Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Director – Mesenchymal Stem Cell Therapies (MD Anderson Cancer Centre) NEW Assistant Professor – Musculoseketal Biology (Keck School of Medicine of USC) Postdoctoral Fellow – Genetic Analysis of Sarcomas (The Francis Crick Institute) Postdoctoral Fellow – Tumor Immunology of Mesenchymal Cells (Lund University) Cell Culture Specialist – Mesenchymal Stem Cells (Tisch MS Research Center of New York) Postdoctoral Research Associate – Cancer and Regenerative Medicine (University of Bristol) Postdoctoral Researcher – Stem Cells and Regenerative Medicine (University Health Network) Postdoctoral – Stem Cell & Biochemical Pharmacology (Genetech) Assistant Professor – Sarcoma or Skeletal Related Malignancies (University of California at Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|